McKesson Corporation Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by McKesson Corporation on April 28, 2026. The report details the entry into a new material definitive agreement regarding the company's credit facilities, effective as of April 24, 2026.
Key Financial Metrics and Debt Structure
The filing focuses on the restructuring of the company's revolving credit facilities rather than reporting period-specific revenue or profit metrics.
- New Facility Size: $5.0 billion revolving line of credit.
- Maturity Date: April 2031.
- Currency Sublimit: $4.5 billion aggregate sublimit for borrowings in Canadian Dollars, British Pound Sterling, and Euros.
- Outstanding Borrowings: No borrowings were outstanding under the terminated existing facilities at the time of the transaction.
- Interest Rate Margins:
- Base Rate Loans: 0% to 0.25%.
- SOFR Rate Loans: 0.625% to 1.25%.
- Foreign Currency Loans: 0.625% to 1.25%.
Material Changes Versus Prior Period
McKesson replaced two existing credit facilities with a single new facility:
- Terminated Facilities: A $1.0 billion 364-day facility (maturing May 2026) and a $4.0 billion five-year facility (maturing November 2029).
- Extension of Maturity: The new facility extends the maturity horizon to 2031, providing greater long-term liquidity certainty compared to the expiring 364-day facility.
- Capacity Increase: The total available revolving credit increased from $5.0 billion (combined existing) to $5.0 billion (new), maintaining total capacity while consolidating terms.
Covenants, Risks, and Management Commentary
Covenants: The New Revolving Credit Facility requires the Company to maintain a total debt to Consolidated EBITDA ratio of no greater than 4.25x to 1.00. This ratio excludes the Medical-Surgical Solutions (MMS) segment's indebtedness and EBITDA. A temporary step-up to 4.75x is permitted upon election following an acquisition involving at least $500 million in cash consideration.
Risks: In the event of a default, lenders may declare all unpaid amounts immediately due and payable. The filing notes that lenders and their affiliates may engage in commercial and investment banking dealings with the Company, receiving customary fees.
Outlook: The filing does not provide specific revenue guidance or operational outlook, focusing solely on the financing arrangement.
Key Facts for Investor Verification
- Verify the current Total Debt to Consolidated EBITDA ratio to ensure compliance with the 4.25x covenant (excluding MMS).
- Confirm the absence of outstanding borrowings under the new facility as of the filing date.
- Monitor the company's acquisition activity, as deals over $500 million in cash consideration may trigger a temporary covenant step-up to 4.75x.
- Review the full text of the Credit Agreement (Exhibit 10.1) for detailed definitions of "Consolidated EBITDA" and specific default triggers.